NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

栓塞治療的全球市場(~2026):產品(栓塞(微球、液體栓塞、線圈)、微導管)、適應症(癌症、血管、動脈瘤、泌尿外科、腎臟)、治療(TACE、TACE)TARE)最終用戶(醫院、診所、ASC)□按地區

Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser(Hospital, Clinics, ASC)-Global Forecast to 2026

出版商 MarketsandMarkets 商品編碼 1006546
出版日期 內容資訊 英文 222 Pages
訂單完成後即時交付
價格
栓塞治療的全球市場(~2026):產品(栓塞(微球、液體栓塞、線圈)、微導管)、適應症(癌症、血管、動脈瘤、泌尿外科、腎臟)、治療(TACE、TACE)TARE)最終用戶(醫院、診所、ASC)□按地區 Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser(Hospital, Clinics, ASC)-Global Forecast to 2026
出版日期: 2021年05月13日內容資訊: 英文 222 Pages
簡介

在預測期內,全球栓塞治療市場預計將以 8.0% 的複合年增長率增長,從 2021 年的 34 億美元增長到 2026 年的 50 億美元。

同樣的因素包括目標疾病負擔增加、新產品開發的投資和投資資金、補貼增加、微創手術需求增加、報銷場景有利、新產品發佈等,我們正在推動市場的增長。與此同時,嚴格的監管框架和替代療法的強勢地位等挑戰預計將抑制進一步的市場增長。

按申請來看,2020 年癌症行業的份額將最大。栓塞治療成功率高、術後併發症少、肝癌和肝細胞癌發病率增加等因素正在推動該行業的發展。從產品來看,由於新產品的批准,栓塞劑部門預計將出現最大的增長。

本報告探討了全球栓塞治療市場、市場定義和概述、價值鏈、冠狀病毒病 (COVID-19) 分析和其他市場影響因素、監管環境、市場。它總結了規模/預測、產品/用途/處理/最終用戶/按地區/主要國家、競爭環境、主要公司簡介等分類。

第 1 章介紹

第二章調查方法

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章市場概覽

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • 價值鏈分析
  • 生態系統
  • 監管分析
  • COVID-19 的影響

第 6 章市場分析/預測:按產品

  • 栓塞劑
    • 液體栓塞劑
    • 微球
  • 栓塞線圈
    • 可拆卸線圈
    • 可推動線圈
  • 栓塞系統
  • 可拆卸氣球
  • 支持設備
    • 微導管
    • 導絲

第 7 章市場分析/預測:按應用

  • 癌症
    • 肝癌
    • 腎癌
    • 肺癌
    • 其他
  • 周圍血管疾病
  • 神經系統疾病
    • 腦動脈瘤
    • 腦動靜脈畸形
  • 泌尿科/腎臟科
    • 良性前列腺增生
    • 其他
  • 胃腸道疾病

第 8 章市場分析/預測:按處理

  • 經導管動脈栓塞術 (TAE)
  • 經導管動脈放射栓塞 (TARE)/選擇性體內放射治療 (SIRT)
  • 經動脈化療栓塞 (TACE)

第 9 章市場分析/預測:按最終用戶

  • 醫院/診所
  • 門診手術中心
  • 其他

第 10 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第11章競爭形勢

  • 概述
  • 市場份額分析
  • 競爭領導力圖
  • 競爭場景

第12章公司簡介

  • 主要公司
    • BOSTON SCIENTIFIC CORPORATION
    • MERIT MEDICAL SYSTEMS
    • TERUMO CORPORATION
    • MEDTRONIC PLC
    • ABBOTT LABORATORIES
    • DEPUY SYNTHES (J&J MEDICAL DEVICES)
    • COOK MEDICAL
    • BALT
    • SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS)
    • KANEKA CORPORATION
    • STRYKER CORPORATION
  • 其他企業
    • PENUMBRA, INC.
    • MERIL LIFE SCIENCES PVT., LTD.
    • ACANDIS GMBH
    • CARDIVA MEDICAL INC. (PART OF HAEMONETICS)
    • SHAPE MEMORY MEDICAL, INC.
    • ARTIO MEDICAL, INC.
    • RAPID MEDICAL
    • IMBIOTECHNOLOGIES LTD.
    • EMBOLINE, INC.

第13章 附錄

目錄
Product Code: MD 7279

The global embolotherapy market is valued at USD 3.4 billion in 2021 and is expected to reach USD 5.0 billion by 2026, at a CAGR of 8.0% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

"The cancer segment, by application, accounted for the largest share of the embolotherapy market in 2020"

In terms of application, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the fifth most common cancer in men and the ninth most common in women.

"The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals"

Based on product, the embolotherapy market is broadly segmented into embolization coils (detachable coils and pushable coils), embolic agents (liquid embolic agents and microspheres), detachable balloons, embolic plug systems, and support devices (microcatheters and guidewires). The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the 'WEB Aneurysm Embolization System.' Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

"Increasing availability of reimbursements in most of developed countries to drive the segment growth of ambulatory surgical centers end user segment"

Based on end users, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. The ambulatory surgery centers segment is projected to register the highest CAGR during the forecast period. The significant growth of this segment can be attributed to the growing adoption of minimally invasive surgical procedures, the increasing number of procedures in ambulatory surgery centers, and the greater availability of reimbursements for target procedures in the US and major European countries.

"The US market, by region, commanded the largest market share in 2020"

On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-45%, Tier 2-34%, and Tier 3- 21%
  • By Designation: C-level-47%, Director-level-33%, and Others-20%
  • By Region: North America-35%, Europe-32%, Asia Pacific-25%, Latin America-6%, and the Middle East & Africa-2%

Some of the prominent players in the embolotherapy market Boston Medical Corporation (US), Terumo Medical Systems (Japan), Medtronic (US), Johnson & Johnson (US), and Stryker Corporation (US). Other key players in the embolization therapy market include Sirtex Medical Limited (US), Abbott Laboratories (US), Acandis GmbH (Germany), Balt (France), Cook Medical (US), Kaneka Corporation (Japan), Penumbra, Inc. (US), Merit Medical Systems (US), Meril Life Sciences Pvt. Ltd. (India), Cardiva (US), Shape Memory Medical Inc. (US), Artio Medical Inc. (US), Rapid Medical (US), Emboline, Inc. (US), and IMbiotechnologies Ltd. (Canada), among others.

Research Coverage

This report studies the embolotherapy market based on product, procedure, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the embolotherapy market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the embolotherapy market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the embolotherapy market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 An indicative list of secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 PRODUCT-BASED MARKET ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 6 EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    • FIGURE 7 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 8 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 9 EMBOLOTHERAPY MARKET SHARE, BY END USER, 2021 VS. 2026
    • FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE EMBOLOTHERAPY MARKET

4 PREMIUM INSIGHTS

  • 4.1 EMBOLOTHERAPY: MARKET OVERVIEW
    • FIGURE 11 THE RISING INCIDENCE OF CHRONIC DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH
  • 4.2 GEOGRAPHIC ANALYSIS: NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS 2026, (USD MILLION)
    • FIGURE 12 THE EMBOLIC AGENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2026
  • 4.3 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS 2026, (USD MILLION)
    • FIGURE 13 THE LIVER CANCER SUBSEGMENT OF THE ONCOLOGY APPLICATION IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • 4.4 EMBOLOTHERAPY MARKET, BY REGION AND PROCEDURE
    • FIGURE 14 TRANSARTERIAL EMBOLIZATION (TAE) PROCEDURE SEGMENT TO HOLD A MAJOR SHARE OF THE ASIA PACIFIC MARKET
  • 4.5 GEOGRAPHIC ANALYSIS: EMBOLOTHERAPY MARKET, BY END USER AND REGION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 AMBULATORY SURGICAL CENTERS SEGMENT TO WITNESS HIGH GROWTH IN EUROPE DURING THE FORECAST PERIOD
  • 4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET
    • FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing target patient population
    • TABLE 1 PRIMARY INCIDENCE OF LIVER CANCER AMONG MEN AND WOMEN (2005 VS. 2030)
    • TABLE 2 GERIATRIC POPULATION, BY REGION (2015 VS. 2030)
      • 5.2.1.2 Rising patient preference for minimally invasive procedures
      • 5.2.1.3 Funding & investments by government and private organizations
      • 5.2.1.4 Technological advancements in embolotherapy devices
      • 5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries
    • TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2021)
    • TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario
      • 5.2.2.2 Strong market positioning of alternative therapies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities offered by emerging markets
      • 5.2.3.2 Expanding applications of embolization devices
    • 5.2.4 CHALLENGES
      • 5.2.4.1 A dearth of skilled surgeons
      • 5.2.4.2 High cost of embolization devices
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 18 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM: EMBOLOTHERAPY MARKET
  • 5.5 REGULATORY ANALYSIS
    • 5.5.1 NORTH AMERICA
      • 5.5.1.1 US
    • TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.5.1.2 Canada
    • TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
    • FIGURE 19 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
    • 5.5.2 EUROPE
    • FIGURE 20 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR)
    • 5.5.3 ASIA PACIFIC
      • 5.5.3.1 Japan
    • TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
      • 5.5.3.2 China
    • TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.5.3.3 India
  • 5.6 IMPACT OF COVID-19 ON EMBOLOTHERAPY MARKET
    • TABLE 10 COVID-19 GUIDELINES FOR TRIAGE OF VASCULAR SURGERY PATIENTS

6 EMBOLOTHERAPY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 11 EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
  • 6.2 EMBOLIC AGENTS
    • TABLE 12 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 13 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 14 EMBOLIC AGENTS, BY TYPE
    • 6.2.1 LIQUID EMBOLIC AGENTS
      • 6.2.1.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict the market growth
    • TABLE 15 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2019-2026 (USD MILLION)
      • 6.2.1.2 Embolotherapy market for liquid embolic agents, by application
    • TABLE 16 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.2.1.3 Embolotherapy market for liquid embolic agents, by Procedure
    • TABLE 17 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY PROCEDURE, 2019-2026 (USD MILLION)
      • 6.2.1.4 Embolotherapy market for liquid embolic agents, by end user
    • TABLE 18 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY END USER, 2019-2026 (USD MILLION)
    • 6.2.2 MICROSPHERES
      • 6.2.2.1 Preference for alternative procedures limits the growth of this market segment
    • TABLE 19 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION, 2019-2026 (USD MILLION)
      • 6.2.2.2 Embolotherapy market for microspheres, by application
    • TABLE 20 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.2.2.3 Embolotherapy market for microspheres, by Procedure
    • TABLE 21 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY PROCEDURE, 2019-2026 (USD MILLION)
      • 6.2.2.4 Embolotherapy market for microspheres, by end user
    • TABLE 22 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY END USER, 2019-2026 (USD MILLION)
  • 6.3 EMBOLIZATION COILS
    • TABLE 23 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS
    • TABLE 24 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 25 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.1 DETACHABLE COILS
      • 6.3.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment
    • TABLE 26 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION, 2019-2026 (USD MILLION)
      • 6.3.1.2 Embolotherapy market for detachable coils, by application
    • TABLE 27 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.3.1.3 Embolotherapy market for detachable coils, by Procedure
    • TABLE 28 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY PROCEDURE, 2019-2026 (USD MILLION)
      • 6.3.1.4 Embolotherapy market for detachable coils, by end user
    • TABLE 29 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY END USER, 2019-2026 (USD MILLION)
    • 6.3.2 PUSHABLE COILS
      • 6.3.2.1 The use of pushable coils increases the risk of non-target vascular blockages, thus restricting their use in various applications
    • TABLE 30 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION, 2019-2026 (USD MILLION)
      • 6.3.2.2 Embolotherapy market for pushable coils, by application
    • TABLE 31 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.3.2.3 Embolotherapy market for pushable coils, by Procedure
    • TABLE 32 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY PROCEDURE, 2019-2026 (USD MILLION)
      • 6.3.2.4 Embolotherapy market for pushable coils, by end user
    • TABLE 33 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY END USER, 2019-2026 (USD MILLION)
  • 6.4 EMBOLIC PLUG SYSTEMS
    • TABLE 34 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION, 2019-2026 (USD MILLION)
    • 6.4.1 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION
    • TABLE 35 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION, 2019-2026 (USD MILLION)
    • 6.4.2 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE
    • TABLE 36 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE, 2019-2026 (USD MILLION)
    • 6.4.3 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER
    • TABLE 37 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER, 2019-2026 (USD MILLION)
  • 6.5 DETACHABLE BALLOONS
    • 6.5.1 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DETACHABLE BALLOONS SUCH AS BALLOON RUPTURE, FAILURE, OR SHRINKAGE MAY LIMIT THE UTILIZATION OF THIS EMBOLIC DEVICE
    • TABLE 38 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2019-2026 (USD MILLION)
    • 6.5.2 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION
    • TABLE 39 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION, 2019-2026 (USD MILLION)
    • 6.5.3 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE
    • TABLE 40 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE, 2019-2026 (USD MILLION)
    • 6.5.4 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER
    • TABLE 41 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER, 2019-2026 (USD MILLION)
  • 6.6 SUPPORT DEVICES
    • TABLE 42 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 43 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION, 2019-2026 (USD MILLION)
    • 6.6.1 MICROCATHETERS
      • 6.6.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption
    • TABLE 44 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION, 2019-2026 (USD MILLION)
      • 6.6.1.2 Embolotherapy market for microcatheters, by application
    • TABLE 45 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.6.1.3 Embolotherapy market for microcatheters, by Procedure
    • TABLE 46 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 47 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY END USER, 2019-2026 (USD MILLION)
    • 6.6.2 GUIDEWIRES
      • 6.6.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth
    • TABLE 48 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION, 2019-2026 (USD MILLION)
      • 6.6.2.2 Embolotherapy market for guidewires, by application
    • TABLE 49 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY APPLICATION, 2019-2026 (USD MILLION)
      • 6.6.2.3 Embolotherapy market for guidewires, by Procedure
    • TABLE 50 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY PROCEDURE, 2019-2026 (USD MILLION)
      • 6.6.2.4 Embolotherapy market for guidewires, by end user
    • TABLE 51 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY END USER, 2019-2026 (USD MILLION)

7 EMBOLOTHERAPY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 52 EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026
  • 7.2 ONCOLOGY
    • TABLE 53 EMBOLOTHERAPY MARKET FOR ONCOLOGY, BY TYPE, 2019-2026
    • TABLE 54 EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2019-2026
    • 7.2.1 LIVER CANCER
      • 7.2.1.1 The rising prevalence of liver cancer is expected to drive segment growth
    • TABLE 55 EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.2 KIDNEY CANCER
      • 7.2.2.1 Preoperative kidney tumor embolization in the treatment of kidney cancer drives the segment growth
    • TABLE 56 EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.3 LUNG CANCER
      • 7.2.3.1 Use of arterial embolotherapy in patients with primary lung cancer to drive the segment growth
    • TABLE 57 EMBOLOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
      • 7.2.3.2 The increasing prevalence of breast cancer is a key factor in the higher adoption of embolotherapy among surgeons
    • TABLE 58 EMBOLOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.4 OTHER CANCERS
    • TABLE 59 EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 PERIPHERAL VASCULAR DISEASES
    • 7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 60 EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 NEUROLOGY
    • TABLE 61 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY TYPE, 2019-2026
    • TABLE 62 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY REGION, 2019-2026 (USD MILLION)
    • 7.4.1 BRAIN ANEURYSM
      • 7.4.1.1 Limited availability of reimbursements across major markets may hinder the market growth
    • TABLE 63 EMBOLOTHERAPY MARKET FOR BRAIN ANEURYSM, BY REGION, 2019-2026 (USD MILLION)
    • 7.4.2 CEREBRAL ARTERIOVENOUS MALFORMATION
      • 7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent
    • TABLE 64 EMBOLOTHERAPY MARKET FOR CEREBRAL ARTERIOVENOUS MALFORMATION, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 UROLOGY & NEPHROLOGY
    • TABLE 65 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 66 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY REGION, 2019-2026 (USD MILLION)
    • 7.5.1 BENIGN PROSTATIC HYPERPLASIA
      • 7.5.1.1 Risks associated with traditional surgery will make patients opt for PAE treatment
    • TABLE 67 EMBOLOTHERAPY MARKET FOR BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2019-2026 (USD MILLION)
      • 7.5.1.2 Advantages offered by the UFE over other techniques is a key factor driving market growth
    • TABLE 68 EMBOLOTHERAPY MARKET FOR UTERINE FIBROIDS, BY REGION, 2019-2026 (USD MILLION)
    • 7.5.2 OTHER UROLOGY & NEPHROLOGY APPLICATIONS
      • 7.5.2.1 Safety and minimal complication with the use of TAE in this segment will drive the market growth
    • TABLE 69 EMBOLOTHERAPY MARKET FOR OTHER UROLOGY & NEPHROLOGY APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
  • 7.6 GASTROINTESTINAL DISORDERS
    • 7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB
    • TABLE 70 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)

8 EMBOLOTHERAPY MARKET, BY PROCEDURE

  • 8.1 INTRODUCTION
    • TABLE 71 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
  • 8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
    • 8.2.1 THE GROWTH OF THIS SEGMENT IS LARGELY DRIVEN DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS
    • TABLE 72 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
    • 8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE SUPPORTS THE GROWTH OF THIS SEGMENT
    • TABLE 73 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE)
    • 8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION
    • TABLE 74 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2019-2026

9 EMBOLOTHERAPY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 75 EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 9.2 HOSPITALS AND CLINICS
    • 9.2.1 RISING INCIDENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
    • TABLE 76 EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019-2026 (USD MILLION)
  • 9.3 AMBULATORY SURGERY CENTERS
    • 9.3.1 INCREASING AVAILABILITY OF REIMBURSEMENTS TO DRIVE THE ADOPTION OF EMBOLOTHERAPY PRODUCTS IN ASCS
    • TABLE 77 EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019-2026 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 78 EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

10 EMBOLOTHERAPY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 79 EMBOLOTHERAPY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 21 NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT
    • TABLE 80 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 81 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 82 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 83 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 84 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 85 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 86 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 87 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Increasing R&D investments in the country drives the market growth
    • TABLE 88 US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 89 US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 90 US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 91 US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 The rising prevalence of cancer supports market growth in Canada
    • TABLE 92 CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 93 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 95 CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 96 EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 97 EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 98 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 99 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 100 EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 EUROPE: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 102 EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 103 EUROPE: EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany is the fastest growing market in Europe
    • TABLE 104 GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 105 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 106 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 107 GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 The rising geriatric population and the high incidence of chronic diseases support market growth in the UK
    • TABLE 108 UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 109 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 110 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 111 UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 The growing geriatric population coupled with the increasing number of target surgeries to support market growth in France
    • TABLE 112 FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 113 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 114 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 115 FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.3.4 SPAIN
      • 10.3.4.1 Increasing government funding for research to support market growth
    • TABLE 116 SPAIN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 117 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 118 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 119 SPAIN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Rising awareness activities to support market growth
    • TABLE 120 ITALY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 121 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 122 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 ITALY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 124 REST OF EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 125 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 126 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 127 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 22 ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT
    • TABLE 128 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 131 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Presence of universal healthcare reimbursement scenario and growing geriatric population-key factors driving market growth
    • TABLE 136 JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 137 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 138 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 139 JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing patient pool and government initiatives for healthcare development supports market growth
    • TABLE 140 CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 141 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 142 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 143 CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Ongoing modernization and infrastructure development in India to support the market growth for embolotherapy
    • TABLE 144 INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 145 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 146 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 147 INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.4.4 SOUTH KOREA
      • 10.4.4.1 Rising R&D and promising clinical trials in the country to positively impact market growth
    • TABLE 148 SOUTH KOREA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 149 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 150 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 151 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Rising research investments and awareness campaigns are the key factors supporting market growth in Australia
    • TABLE 152 AUSTRALIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 153 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 154 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 155 AUSTRALIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 156 REST OF APAC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 157 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 158 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 159 REST OF APAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 160 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 161 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 162 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 163 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 164 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 165 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 166 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 167 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Brazil is a key market in Latin America owing to the modernization of healthcare facilities
    • TABLE 168 BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 169 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 170 BRAZIL : EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 171 BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Availability of advanced care and increasing awareness programs are driving market growth in Mexico
    • TABLE 172 MEXICO: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 173 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 174 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 175 MEXICO: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 176 REST OF LATAM: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 177 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 178 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 179 REST OF LATAM: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA
    • TABLE 180 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 181 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 182 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 183 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 184 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 185 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019-2026 (USD MILLION)
    • TABLE 186 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
    • FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2017 TO 2020
  • 11.2 GLOBAL MARKET SHARE ANALYSIS
    • 11.2.1 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS (2019)
    • FIGURE 24 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
  • 11.3 COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1 STARS
    • 11.3.2 EMERGING LEADERS
    • 11.3.3 PERVASIVE
    • 11.3.4 PARTICIPANTS
    • FIGURE 25 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
    • FIGURE 26 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS)
  • 11.4 COMPETITIVE SCENARIO
    • 11.4.1 PRODUCT LAUNCHES
    • TABLE 187 EMBOLOTHERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, 2017-2020
    • 11.4.2 EXPANSIONS
    • TABLE 188 EMBOLOTHERAPY MARKET: EXPANSIONS, 2017-2020
    • 11.4.3 ACQUISITIONS
    • TABLE 189 EMBOLOTHERAPY MARKET: ACQUISITIONS, 2017-2020

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View)**
  • 12.1 KEY PLAYERS
    • 12.1.1 BOSTON SCIENTIFIC CORPORATION
    • TABLE 190 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
    • FIGURE 27 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
    • 12.1.2 MERIT MEDICAL SYSTEMS
    • TABLE 191 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW
    • FIGURE 28 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT
    • 12.1.3 TERUMO CORPORATION
    • TABLE 192 TERUMO CORPORATION: BUSINESS OVERVIEW
    • FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT
    • 12.1.4 MEDTRONIC PLC
    • TABLE 193 MEDTRONIC PLC: BUSINESS OVERVIEW
    • FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT
    • 12.1.5 ABBOTT LABORATORIES
    • TABLE 194 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT
    • 12.1.6 DEPUY SYNTHES (J&J MEDICAL DEVICES)
    • TABLE 195 DEPUY SYNTHES: BUSINESS OVERVIEW
    • FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT
    • 12.1.7 COOK MEDICAL
    • TABLE 196 COOK MEDICAL: BUSINESS OVERVIEW
    • 12.1.8 BALT
    • TABLE 197 BALT: BUSINESS OVERVIEW
    • 12.1.9 SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS)
    • TABLE 198 SIRTEX MEDICAL LIMITED: BUSINESS OVERVIEW
    • 12.1.10 KANEKA CORPORATION
    • TABLE 199 KANEKA CORPORATION: BUSINESS OVERVIEW
    • FIGURE 33 KANEKA CORPORATION: COMPANY SNAPSHOT
    • 12.1.11 STRYKER CORPORATION
    • TABLE 200 STRYKER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 34 STRYKER CORPORATION: COMPANY SNAPSHOT
  • 12.2 OTHER PLAYERS
    • 12.2.1 PENUMBRA, INC.
    • TABLE 201 PENUMBRA, INC.: BUSINESS OVERVIEW
    • FIGURE 35 PENUMBRA, INC.: COMPANY SNAPSHOT
    • 12.2.2 MERIL LIFE SCIENCES PVT., LTD.
    • TABLE 202 MERIL LIFE SCIENCES PVT., LTD.: BUSINESS OVERVIEW
    • 12.2.3 ACANDIS GMBH
    • TABLE 203 ACANDIS GMBH: BUSINESS OVERVIEW
    • 12.2.4 CARDIVA MEDICAL INC. (PART OF HAEMONETICS)
    • TABLE 204 CARDIVA MEDICAL INC.: BUSINESS OVERVIEW
    • 12.2.5 SHAPE MEMORY MEDICAL, INC.
    • TABLE 205 SHAPE MEMORY MEDICAL, INC..: BUSINESS OVERVIEW
    • 12.2.6 ARTIO MEDICAL, INC.
    • TABLE 206 ARTIO MEDICAL, INC.: BUSINESS OVERVIEW
    • 12.2.7 RAPID MEDICAL
    • TABLE 207 RAPID MEDICAL: BUSINESS OVERVIEW
    • 12.2.8 IMBIOTECHNOLOGIES LTD.
    • TABLE 208 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW
    • 12.2.9 EMBOLINE, INC.
    • TABLE 209 EMBOLINE, INC.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS